Nanjing Bioheng Biotech Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2017-03-27
- Employees
- 101
- Market Cap
- -
- Website
- https://www.bioheng.com
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
Early Phase 1
Recruiting
- Conditions
- SLESystemic SclerosisIIMNMOSDMSMGANCA Associated Vasculitis (AAV)
- Interventions
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT06775912
- Locations
- 🇨🇳
The First People's Hospital of Lianyungang, Lianyungang, Jiangus, China
A Study of RD06-04 in Patients With Active Autoimmune Diseases
Early Phase 1
Not yet recruiting
- Conditions
- SclerosisSLE (Systemic Lupus)ANCA Associated VasculitisIIMSSNMO Spectrum DisorderMSMG
- Interventions
- Drug: RD06-04 cell infusion
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT06548620
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases
Early Phase 1
Recruiting
- Conditions
- Systemic Lupus ErythematosusSystemic SclerosisANCA Associated VasculitisIdiopathic Inflammatory MyopathiesAutoimmune DiseasesSjogren's Syndrome
- Interventions
- Drug: RD06-04 CART Cell Injection
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT06549296
- Locations
- 🇨🇳
Xuzhou Medical University Affiliated Hospital, Xuzhou, Jiangsu, China
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
Early Phase 1
Recruiting
- Conditions
- SLE (Systemic Lupus)Sjogren's SyndromeANCA Associated VasculitisIdiopathic Inflammatory MyopathiesSystemic SclerosisAutoimmune Diseases
- Interventions
- Drug: RD06-04 or RD06-05 CART Cell Injection
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06548607
- Locations
- 🇨🇳
The Third the People's Hospital of Bengbu, Bengbu, Anhui, China
© Copyright 2025. All Rights Reserved by MedPath